

06 JAN 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

James C. Kellerman
Glaxosmithkline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939

In re Application of	:	
BROMIDGE, et al.	:	DECISION ON PETITION
Application No.: 10/501,317	:	
PCT No.: PCT/GB03/00020	:	UNDER 37 CFR 1.137(b)
Int. Filing Date: 07 January 2003	:	
Priority Date: 08 January 2002	:	
Atty. Docket No.: P32969	:	
For: CYCLIC UREA DERIVATIVES WITH 5-HT2C	:	
RECEPTOR ACTIVITY	:	

The petition to revive under 37 CFR 1.137(b) filed 13 July 2004 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" and the prompt filing of the petition satisfies the requirement of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has now provided payment of the full, U.S. Basic National Fee. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being returned to the United States Designated/Elected Office (DO/EO/US) for the preparation and mailing of a "Notification of Missing Requirements" (Form PCT/DO/EO/905) informing applicant that an executed oath or declaration of the inventors and payment of the appropriate surcharge is required.

Derek A. Putonen
Attorney Advisor
Office of PCT Legal Administration
Tel: (571) 272-3294
Fax: (571) 273-0459